Education
About Us
Working with TipRanks
Follow Us
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (HK:8189)
:8189
RESEARCH TOOLSreports
Total Valuation
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has a market cap or net worth of HK$864.43M. The enterprise value is HK$423.72M.
Market CapHK$864.43M
Enterprise ValueHK$423.72M
Share Statistics
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has 1,436,400,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,436,400,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s return on equity (ROE) is -1.26 and return on invested capital (ROIC) is -15.05%.
Return on Equity (ROE)-1.26
Return on Assets (ROA)-0.08
Return on Invested Capital (ROIC)-15.05%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee1.48M
Profits Per Employee-106.93K
Employee Count260
Asset Turnover1.16
Inventory Turnover4.89
Valuation Ratios
The current PE Ratio of Tianjin TEDA Biomedical Engineering Co. Ltd. Class H is -19.51. Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s PEG ratio is 0.31.
PE Ratio-19.51
PS Ratio0.00
PB Ratio4.60
Price to Fair Value24.48
Price to FCF-15.48
Price to Operating Cash Flow-26.09
PEG Ratio0.31
Income Statement
In the last 12 months, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H had revenue of 385.48M and earned -27.80M in profits. Earnings per share was -0.02.
Revenue385.48M
Gross Profit16.97M
Operating Income-28.38M
Pretax Income-38.21M
Net Income-27.80M
EBITDA-20.19M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was 8.04M and capital expenditures -748.74K, giving a free cash flow of 7.30M billion.
Operating Cash Flow8.04M
Free Cash Flow7.30M
Free Cash Flow per Share<0.01
Dividends & Yields
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta>-0.01
52-Week Price Change528.57%
50-Day Moving Average0.42
200-Day Moving Average0.36
Relative Strength Index (RSI)67.30
Average Volume (3m)705.83K
Important Dates
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H upcoming earnings date is May 13, 2025, TBA (Not Confirmed).
Last Earnings DateMar 31, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H as a current ratio of 0.84, with Debt / Equity ratio of 132.11%
Current Ratio0.84
Quick Ratio0.57
Debt to Market Cap0.28
Net Debt to EBITDA-6.66
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has paid 221.32K in taxes.
Income Tax221.32K
Effective Tax Rate>-0.01
Enterprise Valuation
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H EV to EBITDA ratio is -33.53, with an EV/FCF ratio of 0.00.
EV to Sales1.76
EV to EBITDA-33.53
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has HK$92.73M in cash and marketable securities with ¥110.53M in debt, giving a net cash position of HK$17.79M billion.
Cash & Marketable SecuritiesHK$92.73M
Total Debt¥110.53M
Net CashHK$17.79M
Net Cash Per ShareHK$0.01
Tangible Book Value Per ShareHK$0.02
Margins
Gross margin is 3.65%, with operating margin of -7.36%, and net profit margin of -7.21%.
Gross Margin3.65%
Operating Margin-7.36%
Pretax Margin-9.91%
Net Profit Margin-7.21%
EBITDA Margin-5.24%
EBIT Margin-7.36%
Analyst Forecast
The average price target for Tianjin TEDA Biomedical Engineering Co. Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-4.88%
EPS Growth Forecast-34.75%